The effect of national collection and harvesting appears, and the pattern of hospital drug market changes

Pharmaceutical Network Industry Dynamics Recently, IQVIA announced the top ten major products for hospital drug use in the second quarter of 2020.
were, in turn, Garonen, Umbip, Shup Deep, Hessetin, Terisha, Bellin, Noreed, hydrochloric acid right-hand metomedin, come on time, Pumik Lingshu.
Among them, Yangzijiang Pharmaceuticals' two major products in the list is very bright, its Garonen MAT rose 4.5% YoY, in the top position, and the hydrochloric acid right metomide MAT rose 515.2% YoY, also very eye-catching.
National collection effect appears, hospital drug market pattern changes in addition, it is worth noting that the 2019 and the second quarter of 2020 hospital drug use comparison, it can be clearly found that the domestic collection of varieties generally fell, or even fell out of the list, such as the original research varieties Liputo ranking decline, Polvi simply dropped out of the list.
but some products, but also due to the winning bid appeared to rise against the market, such as Yangzijiang Pharmaceuticals' hydrochloric acid right metomi is due to a low decline in the winning bid, the growth rate reached 515.2%.
it is understood that, has been occupying the domestic hydrochloric acid right metomide injection market share.
previously, there was a database of domestic sample hospitals showing that in 2018 Hengrui's right-mercomy injections accounted for 81% of the overall market;
the ratio changes, "4 plus 7" with volume procurement a year later, Hengrui for many years to maintain the right-to-metomy fixed monopoly position no longer exists.
, industry experts say the effects of national harvesting are beginning to show and are have a huge impact on the market sales of the varieties involved.
fact, the industry is also aware that the national market has been the trend of the industry, and will be deeply affected.
but if the enterprise wants to continue to develop, it must either take the initiative to accept and participate deeply, or it must have sufficient strength.
In fact, in the third batch of state mining, foreign-funded enterprises almost collective "great retreat", that is, based on the original research and pharmaceutical enterprises involved in the varieties in the domestic market mostly occupy a leading position, the market share is higher and the action taken.
Specifically, in the third batch of mining, a large number of foreign products have taken high-priced, current price quotation measures, a small number of symbolic choice to reduce the price of about 10%, almost equivalent to giving up the collection market directly.
e.g. antiviral drug Ramifding, the original GlaxoSmithKline basically did not reduce prices, the price and the original market price is similar, 904.2 yuan / box, while the domestic generic drug company Shijiazhuang DikangLongze's price is 11.94 yuan / box, the price difference of more than 80 times.
; O nitrogen flat mouth collapse 5mg effective declared price of 9.26 yuan, the original research price exceeded the limit price nearly doubled;
Overall, in the drug collection, the industry reshuffle, in addition to a few high barriers, a better competitive pattern of varieties, generic high-margin era is gone.
the future, most generic drugs will be collected to achieve price-for-volume, into low-margin varieties, at the same time, China's generic drug market will gradually converse with overseas.
in this environment, the industry generally believes that the future of domestic pharmaceutical companies only in product research and development, quality improvement, to adapt to the development trend of industrial transformation and upgrading, there will be a better way out.